Limiting Free Pricing of New Innovative Drugs After Launch: A Necessity for Payers?
Frankfurt School of Finance and Management, Sonnemannstr. 9-11, 60314, Frankfurt am Main, Germany. a.gandjour@fs.de.
Afschin
A
Gandjour
D016527:Drug Costs / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000191:economics; D005062:European Union; D033161:Government Regulation; D006291:Health Policy / Q000191:economics; D006801:Humans; D062505:Value-Based Purchasing / Q000191:economics*